Original Research

Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study

B P Muzah, S Takuva, M Maskew, S Delany-Moretlwe
Southern African Journal of HIV Medicine | Vol 13, No 4 | a110 | DOI: https://doi.org/10.4102/sajhivmed.v13i4.110 | © 2012 B P Muzah, S Takuva, M Maskew, S Delany-Moretlwe | This work is licensed under CC Attribution 4.0
Submitted: 15 December 2012 | Published: 04 October 2012

About the author(s)

B P Muzah, Wits Reproductive Health and HIV Institute, Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, and School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
S Takuva, Clinical HIV Research Unit, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
M Maskew, Clinical HIV Research Unit, and Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
S Delany-Moretlwe, Wits Reproductive Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa


Share this article

Bookmark and Share

Abstract

Background. The therapeutic goal of antiretroviral therapy (ART) is sustained immune recovery and viral suppression. However, some patients experience poor CD4 cell count responses despite achieving viral suppression. Such discordant immune responses have been associated with poor clinical outcomes.

Objective. We aimed to determine the prevalence of discordant immune response and explore associated factors in a retrospective cohort of patients attending 2 large public sector clinics, during the 6 months following ART initiation.

Methods. Data were analysed from 810 HIV-infected adults initiated on first-line ART at 2 clinics in Johannesburg, between 1 November 2008 and 31 December 2009. Multivariate logistic regression models were used to estimate adjusted odds ratios (AORs) to determine associations between discordant immune response and clinical and demographic factors.

Results. At ART initiation, 65% (n=592) of participants were female, with a mean age of 38.5 years. Median baseline CD4 cell count was 155 cells/mm3, 70% (n=645) of patients had a haemoglobin level >11 g/dl and 88% (n=803) were initiated on stavudine-lamivudine-efavirenz/nevirapine (D4T-3TC-EFV/NVP). Six months after ART initiation, 24% (n=220) of patients had a discordant immune response and 7% (n=67) a discordant virological response. On multivariate analysis, baseline CD cell count ≥200 cells/mm3 (AOR 3.02; 95% confidence interval (CI) 2.08 - 4.38; p<0.001) and moderate anaemia (8.0 - 9.4 g/dl) at baseline (AOR 2.30; 95% CI 1.25 - 4.59; p=0.007) were independently associated with the development of discordant immune response, after adjustment for education level, World Health Organization (WHO) clinical stage and ART regimen.

Conclusions. Discordant immune response following ART initiation was common and associated with baseline anaemia and CD4 cell count in our cohort. Intensive monitoring of at-risk individuals may improve clinical outcomes.

Keywords

discordant, immune response, HIV

Metrics

Total abstract views: 1347
Total article views: 3715

 

Crossref Citations

1. Clinical Outcomes of Tenofovir Versus Zidovudine-based Regimens Among People Living with HIV/AIDS: a Two Years Retrospective Cohort Study
Teshale Ayele, Habtemu Jarso, Girma Mamo
The Open AIDS Journal  vol: 11  issue: 1  first page: 1  year: 2017  
doi: 10.2174/1874613601711010001